complete set of financial statements using the adjusted trial balance presented including the following: Income statement, comprehensive income statement, statement of shareholders's equity, classified balance sheet and statement of cash flow.

Raven Inc.
Adjusted Trial Balance
Quarter ended 3/31/24
	12/31/23	3/31/24
DR	CR	DR	CR
Cash	$ 11,575		$ 9,489
Cash equivalents	$ 14,338		$ 35,282
Marketable securities	$ 40,388		$ 41,656
Accounts receivable, net	$ 23,186		$ 18,077
Inventories	$ 3,956		$ 4,988
Non-trade receivables	$ 25,809		$ 18,904
Other current assets	$ 12,087		$ 12,432
Marketable securities	$ 170,799		$ 158,608
Property, plant and equipment	$ 41,304		$ 39,597
Accumulated depreciation
Other non-current assets	$ 22,283		$ 34,686
Accounts payable		$ 55,888		$ 44,293
Other current liabilities		$ 32,687		$ 36,703
Deferred revenue		$ 7,543		$ 5,546
Commercial paper		$ 11,964		$ 11,969
Term debt		$ 8,784		$ 9,772
Deferred revenue, long-term		$ 2,797		$ -
Notes payable, long-term		$ 93,735		$ 92,989
Long-term taxes payable		$ 33,589		$ 30,948
Other noncurrent liabilities		$ 15,325		$ 23,607
Common stock		$ 40,201		$ 40,970
Retained earnings		$ 8,384		$ 70,400
Dividends			$ 9,766
Accumulated other comprehensive income	$ 2,670		$ 3,454
Net sales		$ 265,595		$ 84,310
Cost of sales	$ 163,756		$ 52,279
Research & development	$ 14,236		$ 3,902
Selling, general & administrative	$ 16,705		$ 4,783
Interest & Dividend income		$ 1,452		$ 1,307
Interest expense	$ 734		$ 890
Realized loss on investments			$ 79
Other income (expense)		$ 38		$ 222
Income tax expense	$ 13,216		$ 3,896
Unrealized gain on marketable securities	$ 1,015			$ 176
Loss on foreign currency translation		$ 269	$ 94
Unrealized loss on derivatives	$ 194		$ 350
$ 578,251	$ 578,251	$ 453,212	$ 453,212